But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Phyox2 data back Dicerna’s nedosiran in just one type of primary hyperoxaluria, where Alnylam already has an 18-month head start.
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.